IONS

Business Context and Reporting Period

Company: Isis Pharmaceuticals, Inc. (Note: Filing text refers to "Isis Pharmaceuticals, Inc." despite the prompt metadata mentioning "IONIS PHARMACEUTICALS INC".)

Reporting Period: Quarterly period ended June 30, 2009 (Form 10-Q).

Business Overview: Isis is a biopharmaceutical company focused on antisense technology and microRNA therapeutics. The company operates primarily through two segments: Drug Discovery and Development, and Regulus Therapeutics (a joint venture with Alnylam). In January 2009, the company completed the sale of its Ibis Biosciences subsidiary to Abbott Molecular Inc. (AMI), which is now reported as discontinued operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 30% year-over-year to $62.6 million. This was driven primarily by increased amortization of upfront payments from the Genzyme strategic alliance and new revenue from the Alnylam collaboration.
• Discontinued Operations: The most significant financial change was the $171.7 million net income from discontinued operations, resulting from the $202.5 million gain on the sale of Ibis Biosciences (net of $30.7 million in taxes). This contrasts with a $5.7 million loss from discontinued operations in the prior year.
• Operating Expenses: Operating expenses increased to $68.0 million (from $53.2 million in 2008) due to expanded clinical development programs (specifically mipomersen Phase 3 trials), increased costs for Regulus Therapeutics, and expanded drug discovery activities.
• Accounting Changes: The company adopted FSP 14-1 regarding convertible debt, which resulted in recording the debt at a discount and increased non-cash interest expense. This adjustment reduced the carrying value of the convertible notes and increased shareholders' equity.

Guidance, Outlook, and Risks

• Outlook: Management expects operating losses to continue over the next several years as the company invests in clinical trials. Revenue is expected to decrease in the third quarter of 2009 when the $50 million upfront payment from OMJP is fully amortized.
• Key Developments:
  • Mipomersen: Positive Phase 3 data reported for homozygous Familial Hypercholesterolemia (FH). Regulatory submission anticipated in the second half of 2010.
  • Regulus: Raised $20 million in Series A financing; achieved a milestone in its GSK collaboration.
  • Alnylam: Entered a new collaboration for single-stranded RNAi (ssRNAi) technology with an $11 million upfront fee.
• Risks:
  • Profitability: The company has an accumulated deficit of $682.3 million and relies on corporate partnerships for funding.
  • Regulatory Approval: Success depends on obtaining FDA approval for pipeline drugs like mipomersen and ISIS 113715.
  • Partnership Dependence: Revenue is concentrated among a few partners (Genzyme, BMS, OMJP, Alnylam). Termination of these agreements could severely impact operations.
  • Intellectual Property: Risks related to patent litigation and the ability to protect proprietary technology.

Investor Verification Checklist

• Revenue Sustainability: Verify the timeline for the amortization of the Genzyme and OMJP upfront payments, as revenue is projected to decline once these are fully recognized.
• Cash Burn Rate: Monitor operating cash flow usage against the $637.5 million cash and investment balance to assess runway without additional financing.
• Mipomersen Regulatory Path: Confirm the status of the FDA submission for homozygous FH and the requirements for the broader indication (outcome study).
• Convertible Debt: Review the terms of the $162.5 million convertible notes (maturity 2027, conversion price $14.63) and the impact of the FSP 14-1 accounting change on future interest expenses.
• Discontinued Operations: Understand that the strong net income for the period is non-recurring and driven by the Ibis sale; focus on the loss from continuing operations ($4.6 million) for ongoing performance.